Sartorius Stedim BiotechSRTOY +2.20%82 Days Inventory is 155.10 as of Mar. 2026, which is 2% below its 10-year median of 157.90. GuruFocus rates SRTOY with a GF Score™ of 82/100 and a GF Value™ of $23.61 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 786 Medical Devices & Instruments companies, Sartorius Stedim Biotech ranks better than 59.92% on this metric.
The historical rank and industry rank for Sartorius Stedim Biotech's Days Inventory or its related term are showing as below:
SRTOY'
s Days Inventory Range Over the Past 10 Years
Min: 110.6 Med: 157.9 Max: 225.8
Current: 155.12
During the past 13 years, Sartorius Stedim Biotech's highest Days Inventory was 225.80. The lowest was 110.60. And the median was 157.90.
SRTOY's Days Inventory is ranked better than 59.92% of 786
companies
in the Medical Devices & Instruments industry
Industry Median: 179.785
vs SRTOY: 155.12
Sartorius Stedim Biotech's Days Inventory
declined
from Mar. 2025 (158.26) to Mar. 2026 (155.10).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Sartorius Stedim Biotech's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.59.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sartorius Stedim Biotech's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.93.
Sartorius Stedim Biotech (OTCPK:SRTOY) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Sartorius Stedim Biotech's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sartorius Stedim Biotech's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Sartorius Stedim Biotech Days Inventory Related Terms
Sartorius Stedim Biotech Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SRTOY vs ISRG, BDX, MDLN: Days Inventory Comparison
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech Days Inventory vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Days Inventory distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech (SRTOY) has a Days Inventory of 155.10 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Sartorius Stedim Biotech and its competitors. This is near median its historical median of 157.90. Over the past decade, Sartorius Stedim Biotech's Days Inventory has ranged from 110.60 to 225.80. According to the industry distribution chart, Sartorius Stedim Biotech ranks #315 out of 786 companies in the Medical Devices & Instruments industry, placing it in the top 40.1%.
Is Sartorius Stedim Biotech's Days Inventory too high?
Sartorius Stedim Biotech's current Days Inventory of 155.10 is near median its 10-year median of 157.90. Over the past 10 years, this metric has ranged from a low of 110.60 to a high of 225.80. The Medical Devices & Instruments industry median Days Inventory is 179.79. Sartorius Stedim Biotech's value of 155.10 is 13.7% below this industry median. Based on the distribution chart, Sartorius Stedim Biotech ranks #315 out of 786 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sartorius Stedim Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Days Inventory compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #315 out of 786 companies for Days Inventory. This puts Sartorius Stedim Biotech in the upper half of its industry. The industry median Days Inventory is 179.79. Sartorius Stedim Biotech's value of 155.10 is 13.7% below this benchmark. Historically, Sartorius Stedim Biotech's own Days Inventory has ranged from 110.60 to 225.80 over the past decade. While the company's 10-year median is 157.90 vs. the industry median of 179.79, Sartorius Stedim Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Devices & Instruments company?
The median Days Inventory among Medical Devices & Instruments companies is 179.79, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius Stedim Biotech's current Days Inventory of 155.10 is 13.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Sartorius Stedim Biotech and its competitors. For the Medical Devices & Instruments industry, the median Days Inventory is 179.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current Days Inventory is 155.10, which is near median its own 10-year median of 157.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (SRTOY) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.61, compared to a current price of $20.90 — trading 11.5% below its estimated fair value. The current Days Inventory is 155.10, which is near median its 10-year median of 157.90 and 13.7% below the Medical Devices & Instruments industry median of 179.79. Sartorius Stedim Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Sartorius Stedim Biotech (SRTOY), the current Days Inventory is 155.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (SRTOY) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of $20.90 is trading 11.5% below its estimated GF Value™ of $23.61.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for SRTOY:
Days Inventory: 155.10 (near median its 10-year median of 157.90)
GF Value™: $23.61 vs. price of $20.90 (11.5% below fair value)
Industry Position: 13.7% below the Medical Devices & Instruments median (#315 of 786)
No single metric tells the full story. See the SRTOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
82GF Score
Get the complete analysis for SRTOY
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRTOY has been successfully added to your 
